BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24414992)

  • 1. Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients.
    Xuan QJ; Wang JX; Nanding A; Wang ZP; Liu H; Lian X; Zhang QY
    Pathol Oncol Res; 2014 Jul; 20(3):619-24. PubMed ID: 24414992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
    Liu H; Wang J; Zhang M; Xuan Q; Wang Z; Lian X; Zhang Q
    Breast Cancer Res Treat; 2017 Nov; 166(1):95-107. PubMed ID: 28730338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
    Dowsett M; Houghton J; Iden C; Salter J; Farndon J; A'Hern R; Sainsbury R; Baum M
    Ann Oncol; 2006 May; 17(5):818-26. PubMed ID: 16497822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.
    Jiang XF; Tang QL; Shen XM; Li HG; Chen LH; Wang XY; Luo X; Lin ZQ; Jiang GY
    Pathol Res Pract; 2012 Dec; 208(12):730-5. PubMed ID: 23122929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
    Pelekanou V; Villarroel-Espindola F; Schalper KA; Pusztai L; Rimm DL
    Breast Cancer Res; 2018 Dec; 20(1):154. PubMed ID: 30558648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
    Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
    Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients.
    Medrek C; Pontén F; Jirström K; Leandersson K
    BMC Cancer; 2012 Jul; 12():306. PubMed ID: 22824040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.
    Knoop AS; Bentzen SM; Nielsen MM; Rasmussen BB; Rose C
    J Clin Oncol; 2001 Jul; 19(14):3376-84. PubMed ID: 11454885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer.
    Ignatov A; Ignatov T; Weissenborn C; Eggemann H; Bischoff J; Semczuk A; Roessner A; Costa SD; Kalinski T
    Breast Cancer Res Treat; 2011 Jul; 128(2):457-66. PubMed ID: 21607586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen.
    Moon YW; Park S; Sohn JH; Kang DR; Koo JS; Park HS; Chung HC; Park BW
    J Cancer Res Clin Oncol; 2011 Jul; 137(7):1123-30. PubMed ID: 21327800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polarized CD163+ tumor-associated macrophages are associated with increased angiogenesis and CXCL12 expression in gastric cancer.
    Park JY; Sung JY; Lee J; Park YK; Kim YW; Kim GY; Won KY; Lim SJ
    Clin Res Hepatol Gastroenterol; 2016 Jun; 40(3):357-365. PubMed ID: 26508473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
    Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
    Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic assessment of tumor-associated macrophages and their histologic localization in invasive breast carcinoma.
    Mwafy SE; El-Guindy DM
    J Egypt Natl Canc Inst; 2020 Jan; 32(1):6. PubMed ID: 32372332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen.
    Boylan M; van den Berg HW; Lynch M
    Ann Oncol; 1998 Feb; 9(2):205-11. PubMed ID: 9553667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
    Gutierrez MC; Detre S; Johnston S; Mohsin SK; Shou J; Allred DC; Schiff R; Osborne CK; Dowsett M
    J Clin Oncol; 2005 Apr; 23(11):2469-76. PubMed ID: 15753463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure.
    Lima L; Oliveira D; Tavares A; Amaro T; Cruz R; Oliveira MJ; Ferreira JA; Santos L
    Urol Oncol; 2014 May; 32(4):449-57. PubMed ID: 24252833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.